Replies to post #10172 on Arch Therapeutics Inc (ARTH)

[Polyphemus]

ARTH filed 10Q on Friday,4:11 pm. Some important reported facts:

Cash on hand - $1.088M
Inventory greater than cash balance - $1.093M - to date, seemingly unsaleable (total $4,696 in revenues in 3 months!)

SG&A expenses $1.263M - greater than cash, 5.3x greater than R&D expense, despite TN claims in 10Q management discussion that ARTH "devoted substantially all of our operational effort to the research, development and regulatory programs necessary to turn our core technology into commercial products".

TN in 10Q: "There exists substantial doubt about the Company's ability to continue as a going concern".

Shareholders need to read this document.